The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study. The Bay Area biotech evaluated 10 days of treatment with t ...
Emerald BioStructures (formerly deCODE biostructures) announced a publication in the December 27, 2009 advance online issue of Nature Biotechnology, detailing the application of structure-based drug ...
HIGH POINT, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential ...
The Food and Drug Administration has accepted a new drug application (NDA) for roflumilast, a topical phosphodiesterase type 4 (PDE4) inhibitor for treating psoriasis in adults and adolescents, ...
PM ET Access the webcast here Denver, CO, April 08, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next ...
CHICAGO -- Adding the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Daliresp) to metformin may help obese women with polycystic ovarian syndrome (PCOS) shed pounds and improve other metabolic ...
NEW YORK CITY -- A topical phosphodiesterase-4 (PDE4) inhibitor produced rapid improvement in seborrheic dermatitis, particularly scalp lesions, a randomized clinical trial showed. Two-thirds of ...
Please provide your email address to receive an email when new articles are posted on . A Bay Area biopharmaceutical firm has announced positive results from its phase 1 clinical trial in healthy ...
DUBLIN--(BUSINESS WIRE)--The "Phosphodiesterase-4 (PDE4) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's ...
(HealthDay)—Inhibition of phosphodiesterase-4 (PDE4), which hydrolyses cyclic adenosine monophosphate (cAMP), may be useful for treating metabolic disorders, according to research published in the May ...
The US Food and Drug Administration's March 21 approval of Celgene's Otezla (apremilast), a small-molecule inhibitor of phosphodiesterase-4 (PDE4), is the first regulatory nod given to a member of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results